glp-1 gip medication long term effects drugs GLP-1 drugs calm inflammation beyond diabetes and weight loss The dual glucose-dependent insulinotropic polypeptide

In a randomized trial (NCT01739049), liraglutide significantly improved binge eating scores and body weight among non-diabetic obese individuals, along with beneficial metabolic and cardiovascular effects

In addition to regaining weight, people returned to pre-drug levels of key markers of cardiometabolic health - including blood pressure and cholesterol - about 17 months after coming off all weight-loss drugs

Adverse events can be reported to the FDA through its MedWatch program to help protect public health

They are unlikely to be open to having you use a GLP-1 immediately after birth if you are nursing, but with a baby who is getting some complementary food after six months or so this is more likely to be an option

ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)

If you are considering whether to stop semaglutide abruptly versus tapering, that decision should be medical, not based on running out of medication